Metabolic Disorders News and Research

RSS

Scientists discover how excess dietary salt drives 'lean MASH'

Fatty liver disease is commonly associated with obesity, yet a growing number of people with normal body weight develop a severe form of the condition.

29 Sep 2026

Marine carbohydrates offer valuable new resources for drug development

The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures.

22 Sep 2026

Study identifies bile acid that helps reduce excess fat accumulation in the liver

Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common condition that causes excess fat to build up in the liver, affecting about one-quarter of adults worldwide.

17 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

MXene-based hydrogel offers dual-action treatment for periodontitis

Periodontitis is a highly prevalent chronic inflammatory disease worldwide. It leads to periodontal tissue destruction, alveolar bone resorption, and ultimately tooth loosening and loss, severely impacting patients' oral function and quality of life.

4 Sep 2026

Crucial brain stem cells rely on metabolic pathways to make decisions

As the human brain takes shape before birth, a remarkable type of stem cell helps give it many of the features that make it distinctly human.

4 Sep 2026

Bright light therapy boosts activity and sleep in older adults

Bright light therapy lamps can improve sleep, activity levels and circadian rhythms of older adults in urban areas who have diminished exposure to natural light, a new study from the University of Surrey reports.

2 Sep 2026

Insilico Medicine releases frontier AI models for drug discovery

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the release of a series of frontier specialist models for chemistry and biology, trained through its MMAI Gym for Science framework.

2 Sep 2026

AI platform uncovers new molecular targets for Alzheimer's disease

Groundbreaking study published in Alzheimer's & Dementia reveals the crucial links between the NAD⁺-mitophagy axis and neurodegeneration.

1 Sep 2026

Newly discovered lung immune cells could transform future flu vaccine design

Influenza continues to cause major illness each year in the United States, leading to more than 35,000 deaths annually. Children, older adults, pregnant individuals, people with weakened immune systems, and those with chronic conditions such as heart disease, metabolic disorders, and cancer are especially vulnerable.

31 Aug 2026

Pomegranate phytobiotics offer natural alternative to synthetic veterinary drugs

Researchers have identified a broad range of biological properties in pomegranate with potential for use in medical applications, including antimicrobial, antiparasitic, antioxidant, immunomodulatory, antidiabetic, anti-inflammatory, liver-supporting, and wound-healing effects.

27 Aug 2026

Review uncovers how tryptophan metabolism affects female reproductive health

In recent years, issues concerning female reproductive health have become a global challenge that cannot be ignored.

24 Aug 2026

Combined bio-histological score prevents overtreatment in liver transplant patients

Long‑term outcomes after liver transplantation remain hampered by complications linked to intensive immunosuppression—infections, cardiovascular events, kidney dysfunction, and metabolic disorders affect 10% to 40% of recipients.

24 Aug 2026

UC Berkeley researchers find new potential treatment for obesity and diabetes

Over the past five years, medications called GLP-1s have revolutionized the treatment of metabolic disorders like obesity, diabetes and fatty liver diseases.

21 Aug 2026

Review outlines how SIRT3 protein regulates global metabolic disorders

A comprehensive review published in Engineering systematically outlines the regulatory capacity of silent information regulator 3 (SIRT3), a mitochondrial deacetylase termed the "head goose molecule", and its negentropic mechanism for intervening global metabolic disorders including type 2 diabetes, obesity, and steatotic liver disease.

21 Aug 2026

New optical control platform blocks and restores neural signaling

DGIST (President Kunwoo Lee) announced that a research team led by Professor Ji Won Um of the Center for Synapse Diversity and Specificity, Department of Brain Sciences, in collaboration with a research team led by Professor Alice Ting at Stanford University, has developed LATeNT, a novel optical control platform that uses light to block signal transmission between neurons and subsequently restore normal signaling.

19 Aug 2026

Why keto appears to lower blood pressure for some people but not others

A narrative review finds that ketogenic diets may modestly lower blood pressure through weight loss, reduced visceral fat, improved insulin sensitivity, fluid and electrolyte shifts, and anti-inflammatory effects. However, effects vary across studies, long-term cardiovascular evidence remains limited, and diet quality, hydration, electrolyte balance, and medication monitoring are important.

17 Aug 2026